Carnitine transporter and holocarboxylase synthetase deficiencies in The Faroe Islands
- 6 April 2007
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 30 (3), 341-349
- https://doi.org/10.1007/s10545-007-0527-9
Abstract
Carnitine transporter deficiency (CTD) and holocarboxylase synthetase deficiency (HLCSD) are frequent in The Faroe Islands compared to other areas, and treatment is available for both disorders. In order to evaluate the feasibility of neonatal screening in The Faroe Islands we studied detection in the neonatal period by tandem mass spectrometry, carrier frequencies, clinical manifestations, and effect of treatment of CTD and HLCSD. We found 11 patients with CTD from five families and 8 patients with HLCSD from five families. The natural history of both disorders varied extensively among patients, ranging from patients who presumably had died from their disease to asymptomatic individuals. All symptomatic patients responded favourably to supplementation with l-carnitine (in case of CTD) or biotin (in case of HLCSD), but only if treated early. Estimates of carrier frequency of about 1:20 for both disorders indicate that some enzyme-deficient individuals remain undiagnosed. Prospective and retrospective tandem mass spectrometry (MS/MS) analyses of carnitines from neonatally obtained filter-paper dried blood-spot samples (DBSS) uncovered 8 of 10 individuals with CTD when using both C0 and C2 as markers (current algorithm) and 10 of 10 when using only C0 as marker. MS/MS analysis uncovered 5 of 6 patient with HLCSD. This is the first study to report successful neonatal MS/MS analysis for the diagnosis of HLCSD. We conclude that CTD and HLCSD are relatively frequent in The Faroe Islands and are associated with variable clinical manifestations, and that diagnosis by neonatal screening followed by early therapy will secure a good outcome.Keywords
This publication has 17 references indexed in Scilit:
- Mutations in the holocarboxylase synthetase geneHLCSHuman Mutation, 2005
- Pharmacokinetics of L-CarnitineClinical Pharmacokinetics, 2003
- Novel OCTN2 mutations: No genotype–phenotype correlations: Early carnitine therapy prevents cardiomyopathyAmerican Journal of Medical Genetics, 2002
- Clinical findings and biochemical and molecular analysis of four patients with holocarboxylase synthetase deficiencyAmerican Journal of Medical Genetics, 2002
- Structure of human holocarboxylase synthetase gene and mutation spectrum of holocarboxylase synthetase deficiencyHuman Genetics, 2001
- Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe IslandsEuropean Journal of Human Genetics, 2001
- Isolation and characterization of mutations in the human holocarboxylase synthetase cDNANature Genetics, 1994
- Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptakeAnnals of Neurology, 1991
- Clinical and biochemical findings on a child with multiple biotin‐responsive carboxylase deficienciesJournal of Inherited Metabolic Disease, 1982
- Urinary excretion of succinylacetone and δ-aminolevulinic acid in patients with hereditary tyrosinemiaClinica Chimica Acta; International Journal of Clinical Chemistry, 1981